Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Learn more about:
Related Clinical Trial
A Phase 1, Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas AMG 319 Lymphoid Malignancy FIH Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Tandem Auto-Allo Transplant for Lymphoma Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas CD4CAR for CD4+ Leukemia and Lymphoma Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma A Study for Patients With Non-Hodgkin’s Lymphomas High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Allo-HSCT as First-line Consolidation in High-risk PTCL A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low ( T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Gemcitabine in NK/T Cell Lymphoma A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma Trial of Endostar Combined With CHOPT for T Cell Lymphoma Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Brief Title

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Official Title

Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Brief Summary

      This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell
      lymphomas who are treated with carfilzomib, lenalidomide and romidepsin in a 3+3 design. The
      phase IIa portion of the study will involve a dose expansion at the MTD to better
      characterize the efficacy and to inform further disease specific studies.

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

MTD (phase Ib)

Secondary Outcome

 overall response rate (orr)


T-cell Lymphomas



Study Arms / Comparison Groups

 Carfilzomib, Romidepsin, Lenalidomide
Description:  All patients will be treated with romidepsin administered intravenously on days 1 and 8 of a 21-day cycle. Lenalidomide will be taken orally daily for days 1-14 of a 21-day cycle. The carfilzomib will be given weekly on days 1, and 8 of a 21-day cycle. Once a MTD is determined this dosing level will be used for the phase IIa portion. Cycles will be continued as above until the patient's wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 2015

Completion Date

January 2023

Primary Completion Date

January 2023

Eligibility Criteria

        Inclusion Criteria:

          -  Pathologically confirmed B- or T-cell lymphomas at the enrolling institution,
             including stage ≥ Ib CTCL, which has relapsed or progressed after at least one
             systemic therapy.

          -  Hodgkin lymphoma is allowed and will be classified as a B-cell lymphoma in the phase
             IIA portion.

          -  Age ≥ 18,

          -  Previous systemic anti-cancer therapy must have been discontinued at least 3 weeks
             prior to treatment and adverse effects must have resolved to ≤Grade 1 or baseline. In
             the phase IIa portion, in progressing subjects, a 2 week washout may be allowed after
             discussion with the MSK Principal Investigator.

          -  Previous radiation, hormonal therapy, and/or surgery must have been discontinued or
             completed at least 2 weeks prior to treatment in this study and adverse effects must
             have resolved. Lymph node or other diagnostic biopsies within 2 weeks are not
             considered exclusionary.

          -  ECOG ≤ 2

          -  Meet the following laboratory criteria:

          -  Absolute neutrophil count 1.0/mm³,

          -  Platelet count 80 K/μ (in the Phase II portion, if thrombocytopenia is due to bone
             marrow involvement platelet count must be 50 K/μL),

          -  Phase Ib subjects must have calculated creatinine clearance 50ml/min by
             Cockcroft-Gault formula, phase IIa subjects must have calculated creatinine clearance
             ≥ 40ml4/min by Cockcroft-Gault formula.

          -  Total bilirubin 1.5 x upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) 3 x ULN

          -  Measurable disease for phase IIa portion only.

          -  Lymphoma (includes CTCL patients who are without evidence of the disease in the skin):
             CT or PET/CT by modified Cheson criteria with incorporation of PET.

          -  CTCL: mSWAT >0, or absolute Sezary count ≥ 1000 cells/μL.

          -  All study participants must be registered into the mandatory Revlimid REMS ® program,
             and be willing and able to comply with the requirements of the REMS ® program.

          -  Short course systemic corticosteroids for disease control, improvement of performance
             status or non-cancer indication (< 7 days) must have been discontinued at least 6 days
             prior to study treatment. Stable ongoing corticosteroid use (≥ 30 days) up to an
             equivalent dose of 15 mg of prednisone is permissible.

          -  Topical steroids that have been used for > 3 weeks may be continued (CTCL only).

          -  Women of reproductive potential must adhere to the scheduled pregnancy testing as
             required in the Revlimid REMS® program. Men must agree to use a latex condom during
             sexual contact with a FCBP even if they have had a successful vasectomy. See Appendix
             A: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control

          -  A female of reproductive potential is a sexually mature female who:

          -  has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally
             postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in
             the preceding 24 consecutive months).

        Exclusion Criteria:

          -  Patients who have a standard curative option for their lymphoid malignancy at current
             state of disease are excluded. For eligibility on this trial, allogeneic stem cell
             transplantation is not to be considered a standard curative option.

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          -  Pregnant females. (Lactating females must agree not to breast feed while taking
             carfilzomib, lenalidomide or romidepsin).

          -  Known hypersensitivity to thalidomide.

          -  The development of erythema multiforme if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          -  Prior use of lenalidomide if discontinued due to toxicity.

          -  Prior therapy with romidepsin if discontinued due to toxicity.

          -  Prior therapy with carfilzomib if discontinued due to toxicity.

          -  Prior therapy with a proteasome inhibitor if discontinued due to toxicity.

          -  Concurrent use of other anti-cancer agents or treatments.

          -  Known seropositive and requiring anti-viral therapy for human immunodeficiency virus
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).

          -  Concurrent malignancy requiring active therapy.

          -  Patients with more than one type of lymphoma may be enrolled after discussion with the
             MSK Principal Investigator.

          -  Known central nervous system or meningeal involvement (in the absence of symptoms
             investigation into central nervous system involvement is not required).

          -  The following known cardiac abnormalities:

          -  Congenital long QT syndrome.

          -  QTc/QTf interval ≥ 480 milliseconds; unless secondary to pacemaker or bundle branch

          -  Myocardial infarction within 6 months of cycle one, day one (C1D1). Subjects with a
             history of myocardial infarction between 6 and 12 months prior to C1D1 who are
             asymptomatic and have had a negative cardiac risk assessment (treadmill stress test,
             nuclear medicine stress test, or stress echocardiogram) since the event may

          -  Other significant ECG abnormalities including 2nd degree atrio-ventricular (AV) block
             type II, 3rd degree AV block.

          -  Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV (see
             Appendix B). In any patient in whom there is doubt, the patient should have a stress
             imaging study and, if abnormal, angiography to define whether or not CAD is present.

          -  An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of ≥2
             mm, measured from isoelectric line to the ST segment). If in any doubt, the patient
             should have a stress imaging study and, if abnormal, angiography to define whether or
             not CAD is present.

          -  Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II
             to IV definitions (see Appendix C) and/or ejection fraction <45% by, echocardiogram,
             or cardiac MRI.

          -  A known history of sustained ventricular tachycardia (VT), ventricular fibrillation
             (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an
             automatic implantable cardioverter defibrillator (AICD).

          -  Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other

          -  Uncontrolled hypertension, i.e., blood pressure (BP) of ≥170/95; patients who have a
             history of hypertension controlled by medication must be on a stable dose (for at
             least one month) and meet all other inclusion criteria.

          -  Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses
             of beta-blockers)

          -  Patients taking drugs that can cause significant QTc/QTf prolongation unless able to
             be switched to non-QTc/QTf prolonging medication or on a stable dose without
             significant QT prolongation (>470 msec).

          -  Concomitant use of significant CYP3A4 inhibitors unless able to be switched to a
             non-CYP3A4 inhibiting medication.

          -  Caution should be used when administering study drugs to patients taking medications
             significantly metabolized by these enzymes refer to
             ( ) for clinically relevant
             medications. Particular attention should be paid to patients receiving warfarin.
             Patient should have coagulation parameters monitored regularly, and warfarin dose
             adjusted accordingly. If these drugs cannot be discontinued or replaced, enrollment
             may be allowed after discussion with MSK PI.




18 Years - N/A

Accepts Healthy Volunteers



Steven Horwitz, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Memorial Sloan Kettering Cancer Center


 University of Nebraska

Study Sponsor

Steven Horwitz, MD, Principal Investigator, Memorial Sloan Kettering Cancer Center

Verification Date

February 2022